UY25824A1 - Antagonista del receptor de vitronectina - Google Patents

Antagonista del receptor de vitronectina

Info

Publication number
UY25824A1
UY25824A1 UY25824A UY25824A UY25824A1 UY 25824 A1 UY25824 A1 UY 25824A1 UY 25824 A UY25824 A UY 25824A UY 25824 A UY25824 A UY 25824A UY 25824 A1 UY25824 A1 UY 25824A1
Authority
UY
Uruguay
Prior art keywords
compound
treatment
useful
receptor antagonist
vitronectin receptor
Prior art date
Application number
UY25824A
Other languages
English (en)
Inventor
Peter J Manley
William H Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY25824A1 publication Critical patent/UY25824A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un compuesto de la fórmula (I) que es un agente antagonista del receptor de vitronectina y es útil para el tratamiento de la osteoporosis: o una sal farmacéuticamente aceptable de éste. También es útil en el tratamiento de trastornos inflamatorios, cancerosos, cardiovasculares, tales como ateroesclerosis y reestenosis y enfermedades en las cuales la resorción del hueso constituye un factor. El compuesto de este invento puede ser útil para el tratamiento de heridas, rechazo de trasplantes, escema, dermatitis por contacto,etc. El compuesto de fórmula (I) se prepara según el esquema (I); Este invento proporciona un método para inhibir el tratamiento de tumores,que comprende administrar escanoladamente una combinación física de un compuesto (I) y un agente antineoplrsico
UY25824A 1998-12-04 1999-11-29 Antagonista del receptor de vitronectina UY25824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
UY25824A1 true UY25824A1 (es) 2001-07-31

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25824A UY25824A1 (es) 1998-12-04 1999-11-29 Antagonista del receptor de vitronectina

Country Status (39)

Country Link
US (1) US6495560B1 (es)
EP (1) EP1146874B1 (es)
JP (1) JP4481504B2 (es)
KR (1) KR100620485B1 (es)
CN (1) CN1147300C (es)
AP (1) AP1534A (es)
AR (1) AR035006A1 (es)
AT (1) ATE277043T1 (es)
AU (1) AU754408B2 (es)
BG (1) BG65118B1 (es)
BR (1) BR9915879A (es)
CA (1) CA2353415A1 (es)
CO (1) CO5150166A1 (es)
CZ (1) CZ20011963A3 (es)
DE (1) DE69920518T2 (es)
DK (1) DK1146874T3 (es)
DZ (1) DZ2954A1 (es)
EA (1) EA003254B1 (es)
EG (1) EG24025A (es)
ES (1) ES2229798T3 (es)
HK (1) HK1042037B (es)
HU (1) HUP0104804A3 (es)
ID (1) ID28811A (es)
IL (2) IL143390A0 (es)
MA (1) MA25265A1 (es)
NO (1) NO318895B1 (es)
NZ (1) NZ511876A (es)
OA (1) OA11724A (es)
PE (1) PE20001563A1 (es)
PL (1) PL195973B1 (es)
PT (1) PT1146874E (es)
SI (1) SI1146874T1 (es)
SK (1) SK7452001A3 (es)
TR (1) TR200101654T2 (es)
TW (1) TW482673B (es)
UA (1) UA71586C2 (es)
UY (1) UY25824A1 (es)
WO (1) WO2000033838A1 (es)
ZA (1) ZA200104398B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
ES2259047T3 (es) * 2000-10-24 2006-09-16 MERCK & CO., INC. Antagonista de receptor de integrina de la dibenzoxazepina.
CA2436130A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
US6872730B2 (en) * 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058760A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
EP1841406A4 (en) * 2004-12-21 2008-06-25 Smithkline Beecham Corp METHOD AND FORMULATIONS
SI2593452T1 (sl) 2010-07-14 2017-06-30 Novartis Ag Heterociklične spojine agonisti receptorja IP
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
PT3929196T (pt) 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
PT910563E (pt) * 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
AU4109297A (en) * 1996-09-27 1998-04-17 Merkler, H. Tank for liquids, particularly for chemically aggressive liquids
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
AU754408B2 (en) 2002-11-14
UA71586C2 (en) 2004-12-15
HUP0104804A2 (hu) 2002-05-29
HK1042037B (zh) 2005-07-29
EP1146874A4 (en) 2002-06-05
HK1042037A1 (en) 2002-08-02
ES2229798T3 (es) 2005-04-16
PT1146874E (pt) 2005-02-28
EP1146874B1 (en) 2004-09-22
DE69920518D1 (de) 2004-10-28
MA25265A1 (fr) 2001-10-01
CO5150166A1 (es) 2002-04-29
ID28811A (id) 2001-07-05
HUP0104804A3 (en) 2002-12-28
CZ20011963A3 (cs) 2001-11-14
JP4481504B2 (ja) 2010-06-16
IL143390A (en) 2006-07-05
BR9915879A (pt) 2002-02-13
NO318895B1 (no) 2005-05-18
AP1534A (en) 2006-01-09
WO2000033838A1 (en) 2000-06-15
BG65118B1 (bg) 2007-03-30
AR035006A1 (es) 2004-04-14
EG24025A (en) 2008-03-26
CA2353415A1 (en) 2000-06-15
SK7452001A3 (en) 2001-12-03
EP1146874A1 (en) 2001-10-24
NZ511876A (en) 2004-02-27
CN1147300C (zh) 2004-04-28
OA11724A (en) 2005-01-26
AU1750200A (en) 2000-06-26
JP2003523931A (ja) 2003-08-12
KR20010080669A (ko) 2001-08-22
IL143390A0 (en) 2002-04-21
ATE277043T1 (de) 2004-10-15
PL348702A1 (en) 2002-06-03
PL195973B1 (pl) 2007-11-30
ZA200104398B (en) 2002-05-29
DE69920518T2 (de) 2005-09-22
EA003254B1 (ru) 2003-02-27
TR200101654T2 (tr) 2002-03-21
KR100620485B1 (ko) 2006-09-13
SI1146874T1 (en) 2005-04-30
PE20001563A1 (es) 2001-02-09
DZ2954A1 (fr) 2004-06-20
EA200100618A1 (ru) 2001-12-24
US6495560B1 (en) 2002-12-17
NO20012732D0 (no) 2001-06-01
CN1334730A (zh) 2002-02-06
DK1146874T3 (da) 2005-01-31
NO20012732L (no) 2001-08-01
TW482673B (en) 2002-04-11
BG105651A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
UY25824A1 (es) Antagonista del receptor de vitronectina
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
PT1115701E (pt) Ureias de arilsulfonanilida
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
EP1470137A4 (en) EDG RECEPTOR AGONISTS
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
CY1108105T1 (el) Ιβανδρονικο οξυ για την θεραπευτικη αντιμετωπιση και την προληψη της οστεoπορωσης
IL172419A0 (en) Piperazine derivatives and methods of use
BR0212251A (pt) Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica, método para o tratamento preventivo e/ou terapêutico de uma doença ou distúrbio decorrente de proliferação celular anormal ou imprópria, e, uso do dito composto ou de um sal farmaceuticamente aceitável do mesmo
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
DK1284952T3 (da) Substituerede chalconer som terapeutiske kompositioner
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
GB9809349D0 (en) Heterocyclic derivatives
BR0105775A (pt) Compostos de n-benzenossulfonil-l-prolina como antagonistas da bradiquinina
DE69911017D1 (en) Arylsulfonanilid-phosphate
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
MY148565A (en) Agent for therapy and/or improvement of disseminated intravascular coagulation
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090416